Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by Poppson Jan 19, 2013 5:06pm

208 Views

Post# 20861977

RE: Analyst Commentary - APO ACST

Thanx, '53, great post

I was going to put up the link to the story when I saw yours....... much more concise than I would have done. Hang in there, folks, and don't forget to put your shares on long-term sale for exhorbitant prices ($7-8-9) to squeeze the short squirrels when they can't find shares to cover. GSSHTA (ssh=short squirrel hunting), Popps

Bullboard Posts

Micromem prepares ARTRA for natural gas field trials